跳至主要内容
临床试验/NCT03248401
NCT03248401已完成4 期

Effect of Cilostazol, a Phosphodiesterase 3 Inhibitor, on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes

Seoul National University Bundang Hospital1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2016年9月26日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
50
试验地点
1
主要终点
Change of carotid artery atherosclerosis

研究概览

简要总结

To investigate the effect of cilostazol compared with aspirin on carotid atherosclerosis in patients with type 2 diabetes mellitus

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age between 30 and 80 years
  • Patients with type 2 diabetes on treatment (HbA1c 6.0-11.0%)
  • Carotid plaque on 3D ultrasound

排除标准

  • Acute bleeding or bleeding tendency
  • Diagnosed with heart failure
  • Suggestive of ischemia on ECG
  • Uncontrolled hypertension
  • Recently diagnosed with peptic ulcer disease
  • Taking other antiplatelet agents
  • Hypersensitivity to salicylic acid
  • Aspirin induced asthma
  • Severe kidney, liver, heart disease

研究组 & 干预措施

Cilostazol group

Experimental

Cilostazol 200 mg or maximal tolerate dose

干预措施: Cilostazol (Drug)

Aspirin group

Active Comparator

Aspirin 100 mg

干预措施: Aspirin (Drug)

结局指标

主要结局

Change of carotid artery atherosclerosis

时间窗: 6 months

Plaque composition

次要结局

  • Change of carotid artery atherosclerosis 2(6 months)
  • Change of carotid artery atherosclerosis 3(6 months)
  • Change of carotid artery atherosclerosis 1(6 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Soo Lim

Professor

Seoul National University Bundang Hospital

研究点 (1)

Loading locations...

相似试验